Dr. Lal PathLabs Ltd

Dr. Lal PathLabs Limited announced that its wholly-owned subsidiary, Dr. Lal Ventures Private Limited, has completed the subscription of a 30% stake in Neuome Technologies Private Limited on August 27, 2026, as previously approved by the board on July 24, 2026, making Neuome an associate of the company.

Dr. Lal PathLabs announced that its board of directors approved the allotment of 2,11,050 equity shares under the Dr. Lal PathLabs Employee Stock Option Plan 2022 on August 06, 2026, increasing the company’s paid-up equity share capital to INR 1,67,84,88,200 divided into 16,78,48,820 equity shares.

Shares of Dr. Lal PathLabs rose 4.27% on Friday, 24 July 2026, after the company reported its Q1 FY27 results. With today's gain, the stock has advanced 10.50% over two trading sessions. It has climbed 31.67% over the last three months and 21.19% over the past one year. The company's consolidated profit after tax increased 27.2% YoY to Rs 170 crore in Q1 FY27. Revenue from operations increased 19.1% YoY to Rs 798 crore in the quarter ended 30 June 2026. EBITDA increased 28.7% YoY to Rs 247 crore, while the EBITDA margin expanded 230 basis points YoY to 31.0%. Profit before tax stood at Rs 229 crore in Q1 FY27, up 26.3% YoY. Material consumed increased 17.8% YoY to Rs 152 crore, while employee benefit expenses rose 7.3% YoY to Rs 133 crore. Fees paid to collection centres increased 20.8% YoY to Rs 116 crore, while other expenses rose 16.3% YoY to Rs 150 crore. Operationally, the company served 8.2 million patients, up 8.2% YoY, while samples processed increased 10.7% YoY to 25.9 million. SwasthFit contributed 27% of revenue during the quarter, unchanged from a year ago. The board declared an interim dividend of Rs 5 per equity share for FY27. The record date for the dividend is 30 July 2026. During the quarter, the company acquired an 80% equity stake in Sunshine Healthcare Limited, Ghana, a diagnostics business, for a consideration not exceeding GHS 45.6 million. It also acquired a 30% equity stake in Neuome Technologies, a company engaged in sample preservation and biobanking solutions, for a consideration not exceeding Rs 3.5 crore. Cash and cash equivalents stood at Rs 1,693 crore as of 30 June 2026. Dr Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. As on 31 March 2026 the company has 312 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore & Mumbai), 7,727 Patient Service Centers (PSCs) and 13,935 Pick-up Points (PUPs). Powered by Capital Market - Live

Dr. Lal PathLabs announced that the Board of Directors of the Company at its meeting held on 24 July 2026, inter alia, have recommended the interim dividend of Rs 5 per equity Share (i.e. 50%) , subject to the approval of the shareholders.

Net profit of Dr Lal Pathlabs rose 28.02% to Rs 169.50 crore in the quarter ended June 2026 as against Rs 132.40 crore during the previous quarter ended June 2025. Sales rose 19.10% to Rs 797.70 crore in the quarter ended June 2026 as against Rs 669.80 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales797.70669.80 19 OPM %31.0328.71 - PBDT273.10215.70 27 PBT228.70181.10 26 NP169.50132.40 28 Powered by Capital Market - Live

Dr. Lal PathLabs will hold a meeting of the Board of Directors of the Company on 24 July 2026.

The stock has gained 6.01% over four sessions, 24.09% in the past three months and 10.24% so far in 2026. Investor sentiment remained positive after the diagnostics company announced on 12 June that it had incorporated a wholly owned subsidiary, DR LAL PATHLABS FZCO, in Dubai, United Arab Emirates. The new entity has been established in the Dubai Multi Commodities Centre (DMCC) and will focus on strategic investments in diagnostics and allied healthcare activities. The company said the subsidiary will explore potential acquisitions, partnerships and joint ventures in the sector. Dr Lal PathLabs has subscribed to the entire share capital of the subsidiary amounting to AED 19.135 million, divided into 19,135 shares of AED 1,000 each, giving it 100% ownership. The move marks the company's entry into the UAE through a dedicated investment vehicle and is expected to support its plans to expand its presence in international diagnostics markets. Dr Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. As on 31 March 2026 the company has 312 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore & Mumbai), 7,727 Patient Service Centers (PSCs) and 13,935 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers. On a consolidated basis, the company posted a net profit of Rs 132 crore in Q4 FY26, down 15.1% YoY. Revenue rose 16.6% YoY to Rs 703 crore in Q4 FY26. Powered by Capital Market - Live

Net profit of Dr Lal Pathlabs declined 15.18% to Rs 131.30 crore in the quarter ended March 2026 as against Rs 154.80 crore during the previous quarter ended March 2025. Sales rose 16.61% to Rs 702.70 crore in the quarter ended March 2026 as against Rs 602.60 crore during the previous quarter ended March 2025. For the full year,net profit rose 3.63% to Rs 504.80 crore in the year ended March 2026 as against Rs 487.10 crore during the previous year ended March 2025. Sales rose 12.25% to Rs 2762.90 crore in the year ended March 2026 as against Rs 2461.40 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales702.70602.60 17 2762.902461.40 12 OPM %26.5828.05 -28.3228.26 - PBDT204.70189.80 8 861.00766.60 12 PBT160.10153.40 4 699.20624.70 12 NP131.30154.80 -15 504.80487.10 4 Powered by Capital Market - Live

The board of Dr Lal Pathlabs at its meeting held on 30 April 2026 has approved the incorporation of wholly owned subsidiary company in Dubai in the name and style of Dr Lal Pathlabs FZCO.

The board of Dr Lal Pathlabs at its meeting held on 30 April 2026 has approved the acquisition of 100% stake in Shahbazkers Diagnostic Centre (SDCPL) from its existing Shareholders. Post acquisition, SDCPL shall become a wholly owned subsidiary of the company.